A new molecule would slow cognitive decline in the early stages of the disease
Should we rejoice in the new treatment validated by the American Medicines Agency (FDA)? It is still too early to claim victory. And yet, this new molecule once morest Alzheimer’s, aimed at reducing the cognitive decline of patients suffering from this neurodegenerative disease, is eagerly awaited following the failed launch of a previous drug with a similar mechanism a year and a half ago. The new treatment, which will be marketed by the pharmaceutical company Eisai under the name Leqembi, is now recommended for patients who have not yet reached an advanced stage of the disease. It represents ‘an important step forward in our battle to tr
